NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Biodexa Pharmaceuticals PLC BDRX
11 fiscal years on record · GBP · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
£-0.00
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 11-year series below
Revenue
Net income
Per share
GBP -0.00
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-38.7%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−27.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+3.6%
−27.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
GBP 18.2M
total assets, end of FY2025
Total assetsGBP 18.2M
CashGBP 8.5M
Gross debtGBP 61,000.00
Net debtGBP -8.5M
Current ratio2.03×
History
11 fiscal years
Every figure from documents filed with the SEC · GBP
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue £B
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income £B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA £B
·
·
·
·
·
·
·
·
·
·
·
Income tax £B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
Net income £B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted £
−0.00
−0.00
−0.02
−1.55
·
·
·
·
·
·
·
Dividend / sh £
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
Shares out B
·
·
·
·
6.74
7.05
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
29 of 29
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed